3B Blackbio Dx Ltd.
BSE: BLACKBIO · Healthcare Service Provider
Snapshot
Unlock 3B Blackbio Dx Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
3B BlackBio Dx Ltd. is a medical technology company specialising in molecular diagnostics, including PCR-based testing and rapid antigen kits under the TRUPCR brand. The company operates globally with a manufacturing base in India and strategic subsidiaries in the UK and Belgium.
Business Model
The company generates revenue through the development, manufacturing, and global distribution of diagnostic solutions and lateral flow technology. It leverages a multi-national footprint to supply healthcare providers across more than 70 countries.
- Global Reach:70+ countries
Management Commentary
Management focuses on expanding the company's diagnostic portfolio through strategic international acquisitions and the integration of advanced molecular technologies. The company maintains a commitment to ISO 13485:2016 quality standards to support its global diagnostic operations.
Growth Outlook
Growth is driven by the expansion of the TRUPCR product suite and the integration of lateral flow technology acquired through Coris BioConcept SRL. The company continues to strengthen its presence in both domestic and international diagnostic markets.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory requirements for medical devices across multiple international jurisdictions, which could impact product approvals.
- Market Competition. The molecular diagnostics sector is highly competitive, with constant pressure to innovate and maintain cost-effective manufacturing.
- Geopolitical and Currency Risk. Operating in over 70 countries exposes the company to fluctuations in foreign exchange rates and geopolitical instability in diverse markets.
- Integration Risk. The successful realisation of synergies from the acquisition of Coris BioConcept SRL remains critical to long-term operational efficiency.
Start your research today
Unlock AI insights, financials, peers and live data on 3B Blackbio Dx Ltd. and 5,000+ companies — free.
Peers · Healthcare Service Provider
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
3B Blackbio Dx Ltd.BLACKBIO | — | — | — | — | 40.0% | — | — | — |
Dr Lal Pathlabs LtdLALPATHLAB | 22,178 | 36.70 | 32.46 | 12.2% | 32.0% | 22.6% | 28.7% | -42.0% |
Vijaya Diagnostic Centre Ltd.VIJAYA | 9,130 | 83.93 | 40.52 | 19.5% | 43.9% | 20.7% | 22.6% | +37.3% |
Metropolis Healthcare Ltd.METROPOLIS | 9,100 | 19.73 | 28.04 | 23.6% | 25.9% | 13.9% | 17.4% | -70.8% |
Thyrocare Technologies Ltd.THYROCARE | 5,857 | 24.86 | 9.89 | 20.6% | 33.7% | 29.3% | 36.5% | -56.0% |
Nephrocare Health ServicesNEPHROPLUS | 5,259 | — | — | — | 22.0% | — | — | — |
As of Mar 2026
Financials
3B Blackbio Dx Ltd.
BSE: BLACKBIO · Healthcare Service Provider
Snapshot
Unlock 3B Blackbio Dx Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
3B BlackBio Dx Ltd. is a medical technology company specialising in molecular diagnostics, including PCR-based testing and rapid antigen kits under the TRUPCR brand. The company operates globally with a manufacturing base in India and strategic subsidiaries in the UK and Belgium.
Business Model
The company generates revenue through the development, manufacturing, and global distribution of diagnostic solutions and lateral flow technology. It leverages a multi-national footprint to supply healthcare providers across more than 70 countries.
- Global Reach:70+ countries
Management Commentary
Management focuses on expanding the company's diagnostic portfolio through strategic international acquisitions and the integration of advanced molecular technologies. The company maintains a commitment to ISO 13485:2016 quality standards to support its global diagnostic operations.
Growth Outlook
Growth is driven by the expansion of the TRUPCR product suite and the integration of lateral flow technology acquired through Coris BioConcept SRL. The company continues to strengthen its presence in both domestic and international diagnostic markets.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory requirements for medical devices across multiple international jurisdictions, which could impact product approvals.
- Market Competition. The molecular diagnostics sector is highly competitive, with constant pressure to innovate and maintain cost-effective manufacturing.
- Geopolitical and Currency Risk. Operating in over 70 countries exposes the company to fluctuations in foreign exchange rates and geopolitical instability in diverse markets.
- Integration Risk. The successful realisation of synergies from the acquisition of Coris BioConcept SRL remains critical to long-term operational efficiency.
Start your research today
Unlock AI insights, financials, peers and live data on 3B Blackbio Dx Ltd. and 5,000+ companies — free.
Peers · Healthcare Service Provider
As of Mar 2026